rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2015-641-645rsp-2156Research ArticleОБЗОРREVIEWЦертолизумаба пэгол в лечении аксиального спондилоартритаCERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITISЭрдесШ. Ф.ErdesSh. F.erdes@irramn.ruФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34АРоссияV.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522Russian Federation201506022016536641645Copyright © Эрдес Ш.Ф., 20162016Эрдес Ш.Ф.Erdes S.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2156

Представлены результаты исследования RAPID-axSpA, в котором впервые оценивалась эффективность ингибитора фактора некроза опухоли α (ФНОα) цертолизумаба пэгола (ЦЗП) при клинических вариантах аксиального спондилоартрита (аксСпА): уже развившемся анкилозирующем спондилите и нерентгенологическом аксСпА. Показано, что ЦЗП эффективен при всех формах аксСпА, вне зависимости от того, имеются ли структурные (рентгенологически выявляемые) повреждения крестцово-подвздошных суставов или они отсутствуют. Также данное исследование впервые показало длительную эффективность ингибиторов ФНОα у пациентов, изначально имеющих высокий уровень С-реактивного белка и/или признаки активного сакроилиита на магнитно-резонансной томограмме.

The paper gives the results of the RAPID-axSpA study that has evaluated for the first time the efficacy of the tumor necrosis factor-α (TNF-α) inhibitor certolizumab pegol (CZP) in treatment of axial spondyloarthritis (axSpA) clinical forms: already developed ankylosing spondylitis and non-radiographic axSpA. CZP was shown to be effective in all forms of axSpA, whether radiographically detected sacroiliitis was present or absent. This study has also demonstrated for the first time the long-term efficacy of TNF-α inhibitors in patients with initially high C-reactive protein level and/or signs of active sacroiliitis by magnetic resonance imaging.

аксиальный спондилоартританкилозирующий спондилитсакроилиитингибиторы фактора некроза опухоли αцертолизумаба пэголaxial spondyloarthritisankylosing spondylitissacroiliitistumor necrosis factor-α inhibitorscertolizumab pegol.ReferencesNesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other antitumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13(11):1323–32. doi: 10.1002/ibd.20225Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other antitumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13(11):1323–32. doi: 10.1002/ibd.20225Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244–79. doi: 10.1016/j.pharmthera.2007.10.001Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244–79. doi: 10.1016/j.pharmthera.2007.10.001Cimzia 200 mg solution for injection. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdf (Accessed 14 December 2012).Cimzia 200 mg solution for injection. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdf (Accessed 14 December 2012).Van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582–91. doi: 10.1002/art.20852Van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582–91. doi: 10.1002/art.20852Van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136–46. doi: 10.1002/art.21913Van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136–46. doi: 10.1002/art.21913Davis JC Jr, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48(11):3230–6. doi: 10.1002/art.11325Davis JC Jr, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48(11):3230–6. doi: 10.1002/art.11325Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58(11):3402–12. doi: 10.1002/art.23969Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58(11):3402–12. doi: 10.1002/art.23969Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, doubleblind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008;58(7):1981–91. doi: 10.1002/art.23606Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, doubleblind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008;58(7):1981–91. doi: 10.1002/art.23606Barkham N, Keen HI, Coates LC, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum. 2009;60(4):946–54. doi: 10.1002/art.24408Barkham N, Keen HI, Coates LC, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum. 2009;60(4):946–54. doi: 10.1002/art.24408Song IH, Hermann K, Haibel H, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis. 2011;70(4):590–6. doi: 10.1136/ard.2010.139667Song IH, Hermann K, Haibel H, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis. 2011;70(4):590–6. doi: 10.1136/ard.2010.139667Landewe R, Rudwaleit M, van der Heijde D, et al. Effect of certolizumab pegol on signs and symptoms of Ankylosing Spondyltitis and non-radiographic axial spondyloarthritis: 24 week results of a double blind randomized placebo-controlled phase 3 axial spondyloarthritis study. Arthritis Rheum. 2012;64(10 Suppl):336–7.Landewe R, Rudwaleit M, van der Heijde D, et al. Effect of certolizumab pegol on signs and symptoms of Ankylosing Spondyltitis and non-radiographic axial spondyloarthritis: 24 week results of a double blind randomized placebo-controlled phase 3 axial spondyloarthritis study. Arthritis Rheum. 2012;64(10 Suppl):336–7.Landewe R, Braun J, Deodhar F, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a doubleblind randomised placebo-controlled Phase 3 study Ann Rheum Dis. 2014;73:39–47. doi: 10.1136/annrheumdis-2013-204231Landewe R, Braun J, Deodhar F, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a doubleblind randomised placebo-controlled Phase 3 study Ann Rheum Dis. 2014;73:39–47. doi: 10.1136/annrheumdis-2013-204231Sieper J, Landewe R, Rudwaleit M, et al. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis. Results from a phase III randomized trial. Arthritis Rheum. 2015;67(3):668–77. doi: 10.1002/art.38973Sieper J, Landewe R, Rudwaleit M, et al. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis. Results from a phase III randomized trial. Arthritis Rheum. 2015;67(3):668–77. doi: 10.1002/art.38973Mease РJ, Dougados M, Davies O, et al. Сertolizumab pegol rapidly reduces peripheral enthesitis and the incidence of tender and swollen joints in patients with active axial spondyloarthritis, including both ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis. 2014;73(Suppl 2):SAT0362.Mease РJ, Dougados M, Davies O, et al. Сertolizumab pegol rapidly reduces peripheral enthesitis and the incidence of tender and swollen joints in patients with active axial spondyloarthritis, including both ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis. 2014;73(Suppl 2):SAT0362.Rudwaleit M, Landewe R, Marzo-Ortega H, et al. Observed incidence rates of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis. Ann Rheum Dis. 2014;73 (Suppl 2):SAT0355. doi: 10.1136/annrheumdis-2014-eular.1806Rudwaleit M, Landewe R, Marzo-Ortega H, et al. Observed incidence rates of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis. Ann Rheum Dis. 2014;73 (Suppl 2):SAT0355. doi: 10.1136/annrheumdis-2014-eular.1806Braun J, Maksymowych WP, Landewe R, et al. Achievement of remission of inflammation in the spine and sacroiliac joints measured by magnetic resonance imaging (MRI) in patients with axial spondyloarthritis, and associations between MRI and clinical remission, over 96 weeks of treatment with certolizumab pegol. Ann Rheum Dis. 2015;74 (Suppl 2):OP0171. doi: 10.1136/annrheumdis-2015-eular.1791Braun J, Maksymowych WP, Landewe R, et al. Achievement of remission of inflammation in the spine and sacroiliac joints measured by magnetic resonance imaging (MRI) in patients with axial spondyloarthritis, and associations between MRI and clinical remission, over 96 weeks of treatment with certolizumab pegol. Ann Rheum Dis. 2015;74 (Suppl 2):OP0171. doi: 10.1136/annrheumdis-2015-eular.1791

The authors declare that there are no conflicts of interest present.